Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 October 2020Website:
http://www.praxismedicines.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:02:09 GMTDividend
Analysts recommendations
Institutional Ownership
PRAX Latest News
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing therapies for CNS disorders, will be attending three upcoming conferences, as announced today.
The average price target suggests a potential upside of 144.7% for Praxis Precision Medicines (PRAX). Although studies have shown this metric may not always be reliable, an increase in earnings estimates could indicate that the stock will experience growth soon.
Praxis Precision Medicines (PRAX) could see an increase in its stock price due to increasing positivity about its earnings potential, as evidenced by its upgrade to a Zacks Rank #2 (Buy).
Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.
Praxis Precision Medicines, Inc. results from the phase 3 Essential3 program, using ulixacaltamide for the treatment of patients with essential tremor, expected in the 2nd half of 2024. Company believes that the essential tremor U.S. market opportunity could be $4 billion. Positive data achieved in phase 2 study, using PRAX-628 for focal epilepsy; Phase 2b study targeting this very same patient population to be initiated 2nd half of 2024.
Does Praxis Precision Medicines, Inc. (PRAX) have what it takes to be a top stock pick for momentum investors? Let's find out.
The average of price targets set by Wall Street analysts indicates a potential upside of 134.4% in Praxis Precision Medicines, Inc. (PRAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Praxis Precision Medicines, Inc. (PRAX) came out with a quarterly loss of $2.97 per share versus the Zacks Consensus Estimate of a loss of $3.15. This compares to loss of $13.04 per share a year ago.
After reaching an important support level, Praxis Precision Medicines, Inc. (PRAX) could be a good stock pick from a technical perspective. PRAX recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
What type of business is Praxis Precision Medicines?
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
What sector is Praxis Precision Medicines in?
Praxis Precision Medicines is in the Healthcare sector
What industry is Praxis Precision Medicines in?
Praxis Precision Medicines is in the Biotechnology industry
What country is Praxis Precision Medicines from?
Praxis Precision Medicines is headquartered in United States
When did Praxis Precision Medicines go public?
Praxis Precision Medicines initial public offering (IPO) was on 16 October 2020
What is Praxis Precision Medicines website?
https://www.praxismedicines.com
Is Praxis Precision Medicines in the S&P 500?
No, Praxis Precision Medicines is not included in the S&P 500 index
Is Praxis Precision Medicines in the NASDAQ 100?
No, Praxis Precision Medicines is not included in the NASDAQ 100 index
Is Praxis Precision Medicines in the Dow Jones?
No, Praxis Precision Medicines is not included in the Dow Jones index
When does Praxis Precision Medicines report earnings?
The next expected earnings date for Praxis Precision Medicines is 09 August 2024